New combo aims to outsmart Treatment-Resistant colorectal cancer
Disease control
Recruiting now
This study tests a new drug, isunakinra, added to an existing immunotherapy (pembrolizumab) in 20 people with advanced colorectal cancer that has not responded to standard treatments. The cancer must have certain genetic features (MSS, TMB-H, KRAS mutation). The goal is to see if…
Phase: PHASE2 • Sponsor: Buzzard Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:56 UTC